The Lancet Regional Health - Europe· 2026Q1
Changing epidemiology and etiology of hepatocellular carcinoma in Europe: implications for clinical practice and health policy
- 1citations
- Q1SCImago
- 2026year
Short summary
Hepatocellular carcinoma (HCC) incidence and deaths are projected to rise over 30% by 2050 in Europe, driven by metabolic dysfunction-associated steatotic liver disease (MASLD) and an aging population, despite expected decreases in viral hepatitis-related cases.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hepatology
HepatologyMedicine